Edward Nash

Achaogen Inc (NASDAQ: AKAO) shares have been rangebound between $10 and $14 since late last year, with a mixed FDA panel vote on its antibiotic treatment candidate plazomicin in early May stifling any potential rally. Update: On June 26, the FDA approved Achaogen's antibiotic for urinary tract...

Achaogen Inc (NASDAQ: AKAO) shares are tumbling Thursday after a mixed FDA panel vote on Plazomicin, its lead candidate to treat serious bacterial infections due to multidrug-resistant enterobacteriaceae. Achaogen shares were slumping 25.3 percent to $10.98 at the time of publication....

Sarepta Therapeutics Inc (NASDAQ: SRPT) presented encouraging long-term cardiac and pulmonary data at the MDA Scientific Conference. The data could provide “additional support for the clinical benefit from Exondys 51 treatment,” SunTrust Robinson Humphrey’s Edward Nash said in a...

At first glance, the FBI's decision to take a second look into the Hillary Clinton email investigation appeared to benefit the biotech sector given her limiting drug price increases rhetoric. However, soon the trend reversed and the opposite has happened. Biotech stocks took a beating last week as...

Drug pricing has been one of the hot topics of the year. As Citron Research's controversial executive editor Andrew Left said last month, “Regulating the price of pharmaceuticals and eliminating price gouging might be the only issue that Trump and Hillary both agree on.” Conversing...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has had a bad year, with its stock down more than 49 percent. However, analysts have noted the company has plenty of potential in the non-alcoholic steatohepatitis (NASH) space, where there are still no FDA-approved therapies. Back in April, Logribel...

Same as many other biopharmaceutical stocks, Sarepta Therapeutics Inc (NASDAQ: SRPT) ad a rocky start to the year. However, its luck changed in September, when the FDA approved Exondys 51 (eteplirsen) for the treatment of Duchenne muscular dystrophy (DMD), leading the stock to more than double in...

The past few months have been great for small cap bluebird bio Inc (NASDAQ: BLUE), which saw its stock appreciate more than 47.6 percent in the last six months and more than 31 percent in the past month alone, largely helped by the entry of its Gen2 LentiGlobin into the clinic. Benzinga recently...

SunTrust said the "logical decision" for the FDA would be to deny approval for Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Eteplirsen drug for the treatment of Duchenne Muscular Dystrophy. DMD is a genetic disorder caused by an absence of dystrophin, a protein that helps keep muscle...

SunTrust said it hasn't changed its benefit-risk profile for Zafgen Inc (NASDAQ: ZFGN)'s beloranib, citing that thromboembolic risks linger on the obesity drug that showed statistically and clinically significant improvements in body weight and glycemic control in a mid-stage trial. Related Link:...

Zafgen Inc (NASDAQ: ZFGN) shares have plunged 67 percent since October 13, after trading above $40 in 2015. SunTrust Robinson Humphrey’s Edward Nash maintained a Buy rating on the company, while reducing the price target from $47 to $25. The partial clinical hold of a trial for beloranib has...